Akesis Pharmaceuticals, Inc.’s (OTC BB: AKES) focus is on the treatment of diabetes and related metabolic disorders. They have a pipeline of innovative oral product candidates that are supported by issued and filed U.S. patents. Their product candidates are proven to lower and control blood glucose levels in patients with Type 2 diabetes. With approximately 20 million people suffering from diabetes in the U.S. alone, blood sugar control via oral drugs represents a multi-billion dollar market opportunity. For further information, visit the Company’s web site at www.akesis.com.
- 17 years ago
QualityStocks
Akesis Pharmaceuticals, Inc.’s (OTC BB: AKES)
Tags Rodman & Renshaw
Related Post
-
QualityStocksNewsBreaks – Nicola Mining Inc. (TSX.V: NIM) (OTCQB: HUSIF) Engages IBN for Corporate Communications Expertise
Nicola Mining (TSX.V: NIM) (OTCQB: HUSIF) is a junior resource company focused on monetizing high-grade…
-
Calidi Biotherapeutics Inc. (NYSE American: CLDI) Committed to Advancing Cancer Care with Innovative RTNova Platform Research
Cancer statistics underscore the urgency of ongoing cancer research and the need for more effective…
-
ONAR Holding Corp. (ONAR) Is ‘One to Watch’
ONAR is scaling a diversified, AI-driven marketing network addressing multiple high-growth industry verticals. The company…